Mode
Text Size
Log in / Sign up

Open-angle glaucoma

Part of Glaucoma

11 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Open-angle glaucoma

172 trials tracked for Open-angle glaucoma: 79 in phase 3 or 4 and 17 with published results. The most-cited published study has 214 citations.

172Trials tracked
79Phase 3 & 4
0Recruiting
17With published results
Phase distribution
Phase 4 34 Phase 3 45 Phase 2 42 Phase 1 3 Other / NA 48
  1. Phase 4 Evaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) Participants Completed · 214 cited
  2. Phase 3 Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed · 131 cited
  3. Phase 3 Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed · 111 cited
  4. Phase 3 Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Completed · 90 cited
  5. Phase 3 Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension Completed · 90 cited
  6. Phase 3 Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed · 77 cited
Show 44 more trials
  1. Phase 3 Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5% Completed · 67 cited
  2. Phase 3 Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension Completed · 31 cited
  3. Phase 3 Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension Completed · 24 cited
  4. Phase 3 Clinical Study Comparing Two Models of a Travoprost Intraocular Implant Completed · 20 cited
  5. Phase 4 Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting Completed · 19 cited
  6. Phase 3 Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension Completed · 18 cited
  7. Phase 3 A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed · 16 cited
  8. Phase 3 Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK) Completed · 12 cited
  9. Phase 3 Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension Completed · 11 cited
  10. Phase 4 Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure Completed · 7 cited
  11. Phase 3 Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension Completed · 6 cited
  12. Phase 4 Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Completed
  13. Phase 4 SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) Completed
  14. Phase 4 Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma Completed
  15. Phase 4 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Completed
  16. Phase 4 Subconjunctival Versus Direct Mitomycin C in Trabeculectomy Completed
  17. Phase 4 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study Completed
  18. Phase 4 Nailfold Capillary Blood Flow With Latanoprost Bunod Completed
  19. Phase 4 Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue Completed
  20. Phase 4 Patient Preference Comparison of AZARGA Versus COSOPT Completed
  21. Phase 4 Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction Completed
  22. Phase 4 Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® Completed
  23. Phase 4 Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada Completed
  24. Phase 4 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed
  25. Phase 4 Efficacy of Changing to DUOTRAV® From Prior Therapy Completed
  26. Phase 4 24-hour IOP-lowering Effect of Brimonidine 0.1% Completed
  27. Phase 4 Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues Completed
  28. Phase 4 Adherence Assessment With Travalert Dosing Aid Completed
  29. Phase 4 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed
  30. Phase 4 Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) Completed
  31. Phase 4 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Completed
  32. Phase 4 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed
  33. Phase 4 Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed
  34. Phase 4 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed
  35. Phase 4 Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery Completed
  36. Phase 4 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed
  37. Phase 4 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed
  38. Phase 4 Efficacy of Changing to TRAVATAN® From Prior Therapy Completed
  39. Phase 4 Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated Completed
  40. Phase 4 Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN Completed
  41. Phase 4 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed
  42. Phase 4 Efficacy of Changing to TRAVATAN® From Prior Therapy Completed
  43. Phase 3 Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension Completed
  44. Phase 3 Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients Completed

Showing the 50 most-cited and recently-updated of 172 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Open-angle glaucoma: what the trials found

Pharmacological management for open-angle glaucoma includes several classes of agents. Beta-blocker monotherapy demonstrated a significant reduction in mean intraocular pressure (IOP) at 8 AM compared to baseline (-25.36% vs -4.71%, p<0.0001) 5. Prostaglandin analogs such as travoprost showed high rates of patients reaching target IOP goals (≤18 mmHg) in both standard and BAK-free formulations [16, 21, 22].

Combination therapies involving Brinzolamide and brimonidine or briminidine consistently demonstrated significant reductions in mean diurnal IOP at week 6 compared to baseline (-24.7% and -22.27% respectively) [11, 13, 14]. Additionally, the Brinzolamide/timolol fixed combination was evaluated for its ability to reach target IOP goals 19.

Other established interventions include Netarsudil ophthalmic solution 4, Mitomycin-C injection 8, and various prostaglandin analogs like Bimatoprost [18, 20] and Monoprost 9.

Recent results — preliminary, needs further review

  • Hydrus Microstent: 43.0% of subjects achieved a ≥20% decrease from baseline in mean diurnal intraocular pressure (MDIOP) at month 12 while maintaining the same or fewer medications 2.
  • SBI-100 Ophthalmic Emulsion, 0.5%: Phase 2 trial currently underway 1.

For the clinician treating this condition

  • Beta-blocker monotherapy is effective for reducing morning intraocular pressure (IOP) 5.
  • Brinzolamide/brimonidine combinations provide significant reductions in mean diurnal IOP at week 6 [11, 13, 14].
  • Travoprost formulations show high success rates in achieving target IOP goals of ≤18 mmHg [16, 21, 22].

AI synthesis of 7 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Glaucoma

Related studies from across the Glaucoma family.

Ocular morbidity prevalence of 43.1% among incarcerated populations in sub-Saharan Africa
Ophthalmology Meta-analysis
Ocular morbidity prevalence of 43.1% among incarcerated populations in sub-Saharan Africa Factors Linked to Eye Conditions in Sub-Saharan African Prisons
This meta-analysis of 3,361 individuals in sub-Saharan African prisons identifies a 43.1% prevalence of ocular morbidity. Key associated fac…
A study of over 3,000 people in African prisons found that age, past injuries, and length of stay are linked to common eye conditions.
Rheumatic diseases linked to 66% higher glaucoma risk in pooled analysis
Ophthalmology Meta-analysis
Rheumatic diseases linked to 66% higher glaucoma risk in pooled analysis Rheumatic Diseases Linked to Higher Risk of Glaucoma
This meta-analysis examined glaucoma incidence and risk in individuals with rheumatic diseases versus the general population. Pooled data sh…
People with rheumatic diseases may face a 66% higher risk of developing glaucoma compared to the general population.
Dysregulation of intraocular immune pathways plays a central role in progressive retinal ganglion cell death
Neurology Sys. Review
Dysregulation of intraocular immune pathways plays a central role in progressive retinal ganglion cell death Immune Pathways Play Central Role in Glaucoma Progression
This systematic review examines the role of intraocular immune pathways, including microglia, astrocytes, and T cells, in glaucoma progressi…
New research highlights how immune system issues inside the eye may contribute to the death of nerve cells in glaucoma patients.
Transconjunctival bleb needling with mitomycin C reduces intraocular pressure in pediatric congenital glaucoma
Ophthalmology Sys. Review
Transconjunctival bleb needling with mitomycin C reduces intraocular pressure in pediatric congenital glaucoma New surgical technique helps manage severe glaucoma in children
This case report describes a 9-year-old patient with refractory primary congenital glaucoma. Transconjunctival bleb needling with mitomycin …
A minimally invasive procedure helped lower high eye pressure in a child with severe glaucoma and a complex surgical history.
Intraluminal stent removal from Paul glaucoma implants significantly reduces intraocular pressure in glaucoma patients
Ophthalmology Meta-analysis
Intraluminal stent removal from Paul glaucoma implants significantly reduces intraocular pressure in glaucoma patients Stent Removal Reduces Eye Pressure in Glaucoma Patients
This meta-analysis of 5 observational studies indicates that removing the intraluminal stent from a Paul glaucoma implant (PGI) significantl…
Removing a specific internal stent from a glaucoma implant can significantly lower eye pressure, especially for patients with high initial p…
Medicinal mushroom-derived compounds show potential for managing oxidative stress and inflammation in ocular conditions
Drug Pipeline Sys. Review
Medicinal mushroom-derived compounds show potential for managing oxidative stress and inflammation in ocular conditions Medicinal mushrooms show promise for several common eye conditions
This narrative review synthesizes evidence regarding medicinal mushroom-derived bioactive compounds, including polysaccharides and triterpen…
Medicinal mushrooms contain compounds that may protect the eyes from inflammation and damage, though more clinical trials are needed to conf…
Oxidative stress and reactive oxygen species mediate retinal ganglion cell death and optic nerve damage
Drug Pipeline Sys. Review
Oxidative stress and reactive oxygen species mediate retinal ganglion cell death and optic nerve damage Oxidative stress and nerve damage drive glaucoma progression
This narrative review explores the role of oxidative stress and reactive oxygen species (ROS) as key mediators of retinal ganglion cell deat…
New research identifies how oxidative stress and reactive oxygen species damage the optic nerve in people with glaucoma.
Postoperative glaucoma occurs in 25.6% of eyes following Boston Type 1 Keratoprosthesis implantation
Ophthalmology Meta-analysis
Postoperative glaucoma occurs in 25.6% of eyes following Boston Type 1 Keratoprosthesis implantation Meta-analysis tracks glaucoma risks after Boston Type 1 Keratoprosthesis
This meta-analysis of 1,482 eyes evaluates glaucoma outcomes following Boston Type 1 Keratoprosthesis (KPro) implantation. The study reports…
A meta-analysis of 1,482 eyes shows that about 25.6% of patients experience some form of glaucoma after a Boston Type 1 Keratoprosthesis pro…
Preservative Free Bimatoprost 0.01% Shows Non Inferiority to Higher Concentration Formulations
Ophthalmology Sys. Review
Preservative Free Bimatoprost 0.01% Shows Non Inferiority to Higher Concentration Formulations Preservative-free bimatoprost shows similar results for glaucoma eye pressure
Preservative-free bimatoprost 0.01% provides comparable intraocular pressure reduction to higher concentrations with improved local tolerabi…
A new look at eye drops shows that preservative-free bimatoprost lowers eye pressure as well as stronger versions with fewer side effects.
Photobiomodulation protocol aims to consolidate preclinical evidence for ophthalmic diseases
Rheumatology Meta-analysis
Photobiomodulation protocol aims to consolidate preclinical evidence for ophthalmic diseases Planning to Review Light Therapy for Common Eye Diseases and Injuries
This is a protocol for a systematic review and meta-analysis, not a completed study. It outlines plans to evaluate photobiomodulation (PBM) …
Experts are planning a large review to see if light therapy can help treat common eye problems like glaucoma and vision loss.
Portable visual-field testing devices show 86% sensitivity and 88% specificity for glaucoma diagnosis
Ophthalmology Meta-analysis
Portable visual-field testing devices show 86% sensitivity and 88% specificity for glaucoma diagnosis Portable devices show promise for diagnosing glaucoma more quickly
This meta-analysis of 2,254 participants with glaucoma and controls evaluated the diagnostic accuracy of portable visual-field testing devic…
New research suggests portable vision tests can accurately detect glaucoma while significantly cutting down the time patients spend in testi…
Glucocorticoid signaling and stress-related neuroendocrine dysregulation influence intraocular pressure and inflammatory pathways in ocular diseases
Rheumatology Sys. Review
Glucocorticoid signaling and stress-related neuroendocrine dysregulation influence intraocular pressure and inflammatory pathways in ocular diseases Stress and hormones may play a role in eye health
This narrative literature overview of 35 studies synthesizes the role of glucocorticoid signaling and stress-related neuroendocrine dysregul…
New research suggests that stress-related hormone changes could influence conditions like glaucoma and other serious eye diseases.